

Electronic supporting information

A Simple and Efficient One-Pot Synthesis of 2-Alkyl/aryl/pyridyl Substituted 2*H*-Chromenes

Lenka Chandrasekhara Rao^a, Nandigama Satish Kumar^a, Nanubolu Jagadeesh Babu^b and Harshadas Mitaram Meshram^{a,*}

^aMedicinal chemistry and pharmacology division, ^bLaboratory of X-ray Crystallography,

CSIR-Indian Institute of Chemical Technology, Hyderabad – 500 007, India

Tel.: +91-40-27191640, Fax: 91-40-27160512

E-mail: hmmeshram@yahoo.com

Contents

X-Ray crystallographic data of compound (3f) -----	S2-3
General procedure -----	S3
Spectral data of all compounds -----	S4-S10
¹ H NMR and ¹³ C of all compounds -----	S11-S39

3f Crystallographic Data

Crystallographic data for 3f: $C_{17}H_{13}Cl_2NO_4$, $M = 366.18$, colourless block, $0.43 \times 0.27 \times 0.14 \text{ mm}^3$, triclinic, space group $P\bar{1}$ (No. 2), $a = 7.7181(13)$, $b = 8.3117(14)$, $c = 14.132(2) \text{ \AA}$, $\alpha = 99.319(3)$, $\beta = 103.875(2)$, $\gamma = 106.460(3)^\circ$, $V = 817.9(2) \text{ \AA}^3$, $Z = 2$, $D_c = 1.487 \text{ g/cm}^3$, $F_{000} = 376$, CCD area detector, MoK α radiation, $\lambda = 0.71073 \text{ \AA}$, $T = 293(2)\text{K}$, $2\theta_{\max} = 50.0^\circ$, 7594 reflections collected, 2869 unique ($R_{\text{int}} = 0.0273$), Final $GooF = 1.121$, $R_I = 0.0554$, $wR2 = 0.1352$, R indices based on 2434 reflections with $I > 2\sigma(I)$ (refinement on F^2), 222 parameters, $\mu = 0.418 \text{ mm}^{-1}$. Crystallographic data for the structure in this paper has been deposited with the Cambridge Crystallographic Data Centre and obtained a unique depository number, CCDC 1048680. The data can be obtained free of charge from <https://summary.ccdc.cam.ac.uk/structure-summary-form> or by writing to the Cambridge Crystallographic Data Centre (CCDC), 12 Union Road, Cambridge CB2 1EZ, UK; fax: +44(0) 1223 336 033; email: deposit@ccdc.cam.ac.uk




Figure caption: The ORTEP diagram of 3f with the atom-numbering scheme. Displacement ellipsoids are drawn at the 30% probability level and H atoms are shown as small spheres of arbitrary radius.

Data collection: X-ray data for the compound were collected at room temperature using a Bruker Smart Apex CCD diffractometer with graphite monochromated MoK α radiation ($\lambda=0.71073\text{\AA}$) with ω -scan method.¹ Preliminary lattice parameters and orientation matrices were obtained from four sets of frames. Unit cell dimensions were determined using 3682 reflections for 3f data. Integration and scaling of intensity data were accomplished using SAINT program.¹ The structure was solved by Direct Methods using SHELXS97² and refinement was carried out by full-matrix least-squares technique using SHELXL97.² Anisotropic displacement parameters were included for all non-hydrogen atoms. O-bound H atom was located from the difference Fourier map. All other H atoms were positioned geometrically and treated as riding on their parent C atoms with C-H distances of 0.93–0.97 \AA , and with $U_{\text{iso}}(\text{H}) = 1.2U_{\text{eq}}(\text{C})$ or $1.5U_{\text{eq}}$ for methyl atoms.


1. SMART & SAINT. Software Reference manuals. Versions 6.28a & 5.625, Bruker Analytical X-ray Systems Inc., Madison, Wisconsin, U.S.A., 2001.
2. Sheldrick, G. M. SHELXS97 and SHELXL97, Programs for crystal structure solution and refinement; University of Gottingen: Germany, 1997.

Experimental Part

General: Salicylaldehydes, β -keto esters, L-proline, TBAB and all solvents were purchased from Sigma Aldrich and Alpha Aesar company and used without further purification as received. All ^1H and ^{13}C NMR spectra were recorded in CDCl_3 or $\text{CDCl}_3+\text{DMSO}$ on Avance 300 or Avance 500 spectrometers. Chemical shifts (δ) are reported in parts per million (ppm) relative to residual CHCl_3 (1H: δ 7.26 ppm, 13C: δ 77.00 ppm) as an internal reference. Coupling constants (J) are reported in Hertz (Hz). Peak multiplicity is indicated as follows: s—singlet, d—doublet, t—triplet, q—quartet, m—multiplet and dd—doublet of doublet. Melting points were measured on a BUCHI melting point machine. IR spectra were recorded on Thermo Nicolet FT/IR-5700 spectrometer. Mass spectra were recorded using Waters mass spectrometer. High resolution mass spectrums (HRMS) were recorded using Applied Bio-Sciences HRMS spectrometer at national center for mass spectroscopy-IICT.


General procedure: In a typical experiment the salicylaldehyde (1mmol), β -keto ester or β -diketone (1mmol), L-proline (30 mol%) catalytic amount of TBAB (5 mol%) in H_2O (2 ml) were placed in a 10ml round-bottomed flask and stirred at room temperature for 6 h. After completion of the reaction (monitored by TLC), extracted with ethylacetate and dried over Na_2SO_4 and the solvent was removed under reduced pressure and the crude product was purified by column chromatography using ethyl acetate/hexane. All compounds were characterized by (NMR, Mass, and IR) spectral data. Further, we have done the reaction up to 5g scales.

Ethyl 2-hydroxy-2-(pyridin-4-yl)-2H-chromene-3-carboxylate (table 2, 3a):




White solid; Mp 145-147 °C; IR: ν_{max} 3061, 2919, 2808, 2649, 1717, 1632, 1602, 1451, 1360, 1209, 1157, 1068, 926, 762 cm⁻¹; ¹H NMR (300 MHz, CDCl₃+DMSO): δ 8.55 (d, *J* = 5.47 Hz, 2H), 7.94 (br-s, 1H), 7.80 (s, 1H), 7.56 (d, *J* = 5.47 Hz, 2H), 7.35 (t, *J* = 7.36 Hz, 2H), 7.04 (t, *J* = 7.36 Hz, 1H), 6.94 (d, *J* = 8.49 Hz, 1H), 3.91-4.13 (m, 2H), 1.05 (t, *J* = 7.18 Hz, 3H); ¹³C NMR (75 MHz, CDCl₃+DMSO): δ 163.7, 151.9, 151.7, 148.5, 134.4, 132.0, 128.4, 124.9, 121.4, 121.1, 118.0, 116.2, 97.0, 60.2, 13.4; m/z (ESI); 298 [M+H]⁺, 320 [M+23]⁺. HRMS calcd for C₁₇H₁₆NO₄: 298.10639, found: 298.10622.

Ethyl 6-chloro-2-hydroxy-2-(pyridin-4-yl)-2H-chromene-3-carboxylate (table 2, 3b):




White solid; Mp 165-167 °C; IR: ν_{max} 3068, 2975, 2736, 1703, 1621, 1600, 1438, 1265, 1209, 1145, 1054, 912, 739 cm⁻¹; ¹H NMR (300 MHz, CDCl₃+DMSO): δ 8.56 (d, *J* = 5.29 Hz, 2H), 8.11 (br-s, 1H), 7.74 (s, 1H), 7.54 (d, *J* = 5.29 Hz, 2H), 7.36 (s, 1H), 7.30 (dd, *J*₁ = 8.69 Hz, *J*₂ = 1.51 Hz, 1H), 6.90 (d, *J* = 8.49 Hz, 1H), 3.92-4.11 (m, 2H), 1.06 (t, *J* = 8.49 Hz, 3H); ¹³C NMR (75 MHz, CDCl₃+DMSO): δ 162.4, 150.5, 149.5, 147.8, 132.2, 130.6, 126.7, 125.4, 125.0, 120.2, 118.7, 116.9, 96.5, 59.5, 12.6; m/z (ESI); 332 [M+H]⁺. HRMS calcd for C₁₇H₁₅ClNO₄: 332.06750, found: 332.06841.

Ethyl 6-bromo-2-hydroxy-2-(pyridin-4-yl)-2H-chromene-3-carboxylate (table 2, 3c):



White solid; Mp 172-174 °C; IR: ν_{max} 3071, 2986, 2748, 1704, 1628, 1605, 1447, 1284, 1217, 1134, 1062, 906, 731 cm⁻¹; ¹H NMR (300 MHz, CDCl₃+DMSO): δ 8.60 (m, 2H), 7.99 (s, 1H), 7.74 (s, 1H), 7.40-7.60 (m, 4H), 6.83-6.91 (m, 1H), 3.92-4.14 (m, 2H), 1.06 (t, *J* = 7.74 Hz, 3H); ¹³C NMR (75 MHz, CDCl₃+DMSO): δ 163.1, 151.1, 150.6, 148.4, 134.0, 132.7, 130.2, 125.9, 120.8, 119.7, 117.9, 112.8, 97.0, 60.1, 13.1; m/z (ESI); 376 [M+H]⁺. HRMS calcd for C₁₇H₁₅BrNO₄: 376.01771, found: 376.01790.

Ethyl 2-hydroxy-6-nitro-2-(pyridin-4-yl)-2H-chromene-3-carboxylate (table 2, 3d):




White solid; Mp 191-193 °C; IR: ν_{max} 3063, 2978, 2732, 1706, 1625, 1602, 1439, 1277, 1219, 1144, 1051, 917, 726 cm⁻¹; ¹H NMR (300 MHz, CDCl₃+DMSO): δ 8.61 (d, *J* = 5.48 Hz, 2H), 8.37 (d, *J* = 2.26 Hz, 1H), 8.22 (dd, *J*₁ = 6.42 Hz, *J*₂ = 2.45 Hz, 1H), 7.93 (s, 1H), 7.53 (d, *J* = 5.85 Hz, 2H), 7.06 (d, *J* = 9.06 Hz, 1H), 3.98-4.12 (m, 2H), 1.09 (t, *J* = 6.99 Hz, 3H); ¹³C NMR (75 MHz, CDCl₃+DMSO): δ 161.9, 148.0, 140.5, 131.9, 126.2, 123.4, 120.1, 117.2, 115.9, 59.7, 12.6; m/z (ESI); 343 [M+H]⁺. HRMS calcd for C₁₇H₁₅N₂O₆: 343.09164, found: 343.09246.

Ethyl 2,7-dihydroxy-2-(pyridin-4-yl)-2H-chromene-3-carboxylate (table 2, 3e):




White solid; Mp 250-252 °C; IR: ν_{max} 3305, 3086, 2966, 2718, 1708, 1608, 1601, 1415, 1266, 1208, 1145, 1058, 926, 746 cm⁻¹; ¹H NMR (300 MHz, CDCl₃+DMSO): δ 9.90 (br-s, 1H), 8.53 (d, *J* = 4.72 Hz, 2H), 7.88 (s, 1H), 7.74 (s, 1H), 7.50 (d, *J* = 4.72 Hz, 2H), 7.21 (d, *J* = 8.31 Hz, 1H), 6.34 (s, 1H), 3.84-4.06 (m, 2H), 3.44 (s, 3H), 1.03 (t, *J* = 6.99 Hz, 3H); ¹³C NMR (75 MHz, CDCl₃+DMSO): δ 162.6, 160.7, 152.4, 151.1, 147.4, 133.7, 128.7, 119.9, 119.6, 109.1, 108.6, 101.6, 96.5, 58.5, 12.4; m/z (ESI); 314 [M+H]⁺. HRMS calcd for C₁₇H₁₆NO₅: 314.10187, found: 314.10230.

Ethyl 6,8-dichloro-2-hydroxy-2-(pyridin-4-yl)-2H-chromene-3-carboxylate (table 2, 3f):




White solid; Mp 173-175 °C; IR: ν_{max} 3324, 3023, 2938, 2842, 1703, 1639, 1519, 1446, 1281, 1228, 1035, 824, 737 cm⁻¹; ¹H NMR (300 MHz, CDCl₃+DMSO): δ 8.59 (d, *J* = 5.95 Hz, 2H), 8.36 (br-s, 1H), 7.72 (s, 1H), 7.56 (d, *J* = 6.10 Hz, 2H), 7.41 (d, *J* = 2.44 Hz, 1H), 7.31 (d, *J* = 2.29 Hz, 1H), 3.94-4.11 (m, 2H), 1.07 (t, *J* = 7.17 Hz, 3H); ¹³C NMR (75 MHz, CDCl₃+DMSO): δ 162.6, 150.3, 148.3, 146.1, 132.1, 130.8, 132.1, 130.8, 126.7, 125.8, 125.3, 120.8, 120.6, 60.2, 13.0; m/z (ESI); 366 [M+H]⁺. HRMS calcd for C₂₂H₁₄O₄Cl₂: 366.02892, found: 366.02944.

Ethyl 6,8-dibromo-2-hydroxy-2-(pyridin-4-yl)-2H-chromene-3-carboxylate (table 2, 3g):




White solid; Mp 248-250 °C; IR: ν_{max} 3324, 3019, 2962, 2831, 1702, 1616, 1524, 1416, 1229, 1208, 1024, 819, 733 cm⁻¹; ¹H NMR (300 MHz, CDCl₃+DMSO): δ 8.32-8.68 (m, 3H), 7.66-7.79 (m, 2H), 7.48-7.61 (m, 3H), 3.90-4.12 (m, 2H), 1.07 (t, *J* = 7.17 Hz, 3H); ¹³C NMR (75 MHz, CDCl₃+DMSO): δ 162.6, 150.3, 148.2, 147.6, 136.2, 132.0, 129.7, 126.6, 120.9, 120.5, 112.6, 110.6, 60.2, 13.0; m/z (ESI); 456 [M+H]⁺. HRMS calcd for C₂₂H₁₄NO₄Br₂: 456.92458, found: 456.92025.

Ethyl 2-hydroxy-6,8-diiodo-2-(pyridin-4-yl)-2H-chromene-3-carboxylate (table 2, 3h):




White solid; Mp 163-165 °C; IR: ν_{max} 3418, 3058, 2926, 2853, 1699, 1625, 1537, 1434, 1278, 1218, 1011, 812, 728 cm⁻¹; ¹H NMR (300 MHz, CDCl₃+DMSO): δ 8.52-8.64 (m, 2H), 8.37-8.46 (m, 1H), 8.05 (d, *J* = 2.08 Hz, 1H), 7.85 (d, *J* = 1.89 Hz, 1H), 7.74 (s, 1H), 7.50 (d, *J* = 4.34 Hz, 2H), 3.89-4.08 (m, 2H), 1.02 (t, *J* = 6.99 Hz, 3H); ¹³C NMR (75 MHz, CDCl₃+DMSO): δ 161.3, 149.7, 149.3, 147.3, 145.9, 135.3, 131.2, 125.0, 119.7, 119.4, 97.1, 84.9, 82.7, 58.8, 12.0; m/z (ESI); 550 [M+H]⁺. HRMS calcd for C₂₂H₁₄NO₄I₂: 549.89859, found: 549.90067.

Ethyl 7-(allyloxy)-2-hydroxy-2-(pyridin-4-yl)-2H-chromene-3-carboxylate (table 2, 3i):




Semi solid; IR: ν_{max} 2984, 1708, 1611, 1560, 1502, 1368, 1284, 1208, 1120, 1002, 756 cm⁻¹; ¹H NMR (300 MHz, CDCl₃): δ 8.49 (d, *J* = 5.95 Hz, 2H), 7.74 (s, 1H), 7.52 (d, *J* = 6.26 Hz, 2H), 7.19 (d, *J* = 8.39 Hz, 1H), 6.61 (dd, *J*₁ = 8.39 Hz, *J*₂ = 2.44 Hz, 1H), 6.49 (d, *J* = 2.14 Hz, 1H), 5.96-6.05 (m, 1H), 5.37-5.42 (m, 1H), 5.27-5.31 (m, 1H), 4.51 (td, *J*₁ = 3.82 Hz, *J*₂ = 1.53 Hz, 2H), 4.07-4.14 (m, 2H), 1.11 (t, *J* = 7.17 Hz, 3H); ¹³C NMR (75 MHz, CDCl₃): δ 164.9, 162.8, 153.5, 151.6, 149.2, 135.3, 132.3, 129.9, 121.9, 120.9, 118.2, 111.4, 110.2, 102.2, 97.8, 69.0, 60.9, 13.9; m/z (ESI); 354 [M+H]⁺.

Ethyl 7-(benzyloxy)-2-hydroxy-2-(pyridin-4-yl)-2H-chromene-3-carboxylate (table 2, 3j):



White solid; Mp 163-165 °C; IR: ν_{max} 3419, 3058, 2984, 2830, 1712, 1611, 1568, 1460, 1293, 1218, 1075, 1018, 818, 702 cm⁻¹; ¹H NMR (300 MHz, CDCl₃+DMSO): δ 8.56 (d, *J* = 5.85 Hz, 2H), 7.78 (s, 1H), 7.55 (d, *J* = 5.85 Hz, 2H), 7.24-7.42 (m, 6H), 6.68 (dd, *J*₁ = 6.42 Hz, *J*₂ = 2.08 Hz, 1H), 6.55 (d, *J* = 2.08 Hz, 1H), 5.06 (s, 2H), 3.90-4.11 (m, 2H), 1.05 (t, *J* = 7.17 Hz, 3H); ¹³C NMR (75 MHz, CDCl₃+DMSO): δ 163.4, 161.6, 152.9, 151.5, 148.1, 135.5, 133.9, 129.1, 127.7, 127.2, 126.6, 121.4, 120.6, 111.2, 108.8, 101.4, 96.9, 69.2, 59.5, 13.0; m/z (ESI); 404 [M+H]⁺.


Ethyl 2-hydroxy-7-(2-methoxy-2-oxoethoxy)-2-(pyridin-4-yl)-2H-chromene-3-carboxylate (table 2, 3k):



White solid; Mp 153-155 °C; IR: ν_{max} 3073, 2790, 2645, 1758, 1705, 1611, 1566, 1454, 1293, 1220, 1065, 999, 855, 718 cm⁻¹; ¹H NMR (300 MHz, CDCl₃): δ 8.48-8.53 (m, 2H), 7.74 (s, 1H), 7.51 (dd, *J*₁ = 4.58 Hz, *J*₂ = 1.68 Hz, 2H), 7.22 (d, *J* = 8.54 Hz, 1H), 6.60-6.64 (m, 1H), 6.44 (d, *J* = 2.29 Hz, 1H), 4.62 (s, 2H), 4.00-4.14 (m, 2H), 3.79

(s, 3H), 1.14 (t, $J = 7.17$ Hz, 3H); ^{13}C NMR (75 MHz, CDCl_3): δ 168.6, 164.6, 161.5, 153.4, 152.1, 148.1, 134.8, 130.0, 122.1, 121.2, 112.3, 109.7, 102.1, 97.8, 64.9, 60.8, 52.3, 13.8; m/z (ESI); 386 [M+H] $^+$.

Ethyl 7-(2-ethoxy-2-oxoethoxy)-2-hydroxy-2-(pyridin-4-yl)-2H-chromene-3-carboxylate (table 2, 3l):



White solid; Mp 157-159 °C; IR: ν_{max} 3068, 2792, 2656, 1751, 1704, 1609, 1558, 1446, 1287, 1224, 1068, 976, 856, 727 cm^{-1} ; ^1H NMR (300 MHz, CDCl_3): δ 8.41-8.49 (m, 2H), 7.72 (s, 1H), 7.52 (dd, $J_1 = 4.73$ Hz, $J_2 = 1.37$ Hz, 2H), 7.17-7.21 (m, 1H), 6.61 (d, $J = 8.39$ Hz, 1H), 6.43-6.45 (m, 1H), 4.59 (s, 2H), 4.24 (q, $J = 7.17$ Hz, 2H), 3.99-4.13 (m, 2H), 1.28 (t, $J = 7.17$ Hz, 3H), 1.14 (t, $J = 7.01$ Hz, 3H); ^{13}C NMR (75 MHz, CDCl_3): δ 168.1, 164.5, 161.6, 153.4, 152.1, 148.5, 149.8, 134.8, 129.9, 122.1, 121.2, 112.3, 109.7, 102.1, 97.8, 65.1, 61.5, 60.8, 14.0, 13.8; m/z (ESI); 400 [M+H] $^+$.

Ethyl 6-bromo-2-hydroxy-2-(4-nitrophenyl)-2H-chromene-3-carboxylate (table 2, 3m):




White solid; Mp 127-129 °C; IR: ν_{max} 3054, 2789, 2648, 1707, 1605, 1444, 1275, 1213, 1062, 873, 729 cm^{-1} ; ^1H NMR (300 MHz, CDCl_3 +DMSO): δ 8.20 (d, $J = 8.88$ Hz, 2H), 8.02 (s, 1H), 7.83 (d, $J = 8.69$ Hz, 2H), 7.75 (s, 1H), 7.52 (d, $J = 2.08$ Hz, 1H), 7.44 (dd, $J_1 = 6.42$ Hz, $J_2 = 2.27$ Hz, 1H), 6.85 (d, $J = 8.49$ Hz 1H), 3.92-4.13 (m, 2H), 1.09 (t, $J = 7.18$ Hz, 3H); ^{13}C NMR (75 MHz, CDCl_3 +DMSO): δ 162.9, 150.4, 149.4, 146.7, 133.9, 132.5, 130.1, 126.9, 125.8, 121.9, 119.6, 117.8, 112.7, 97.1, 60.0, 13.1; m/z (ESI); 420 [M+H] $^+$.

Ethyl 6-chloro-2-hydroxy-2-(4-nitrophenyl)-2H-chromene-3-carboxylate (table 2, 3n):




White solid; Mp 121-123 °C; IR: ν_{max} 3072, 2803, 2654, 1709, 1606, 1448, 1275, 1229, 1062, 970, 848, 734 cm^{-1} ; ^1H NMR (300 MHz, CDCl_3 +DMSO): δ 8.20 (d, $J = 8.88$ Hz, 2H), 8.02 (s, 1H), 7.83 (d, $J = 8.69$ Hz, 2H), 7.75 (s, 1H), 7.38 (d, $J = 2.45$ Hz, 1H), 7.31 (dd, $J_1 = 6.23$ Hz, $J_2 = 2.45$ Hz, 1H), 6.91 (d, $J = 8.69$ Hz 1H), 3.89-4.13 (m, 2H), 1.09 (t, $J = 7.18$ Hz, 3H); ^{13}C NMR (75 MHz, CDCl_3 +DMSO): δ 162.8, 149.9, 149.3, 146.6, 132.6, 131.0, 127.1, 126.9, 125.5, 121.8, 118.9, 117.3, 97.1, 59.9, 13.1; m/z (ESI); 376 [M+H] $^+$.

Methyl 6-bromo-2-hydroxy-2-methyl-2H-chromene-3-carboxylate (table 3, 3aa):




White solid; Mp 106-108 °C; IR: ν_{max} 3338, 3058, 2975, 1696, 1617, 1524, 1339, 1243, 1051, 945, 760 cm⁻¹; ¹H NMR (300 MHz, CDCl₃): δ 7.50 (s, 1H), 7.40 (dd, J_1 = 8.69 Hz, J_2 = 2.27 Hz, 1H), 7.36 (d, J = 2.27 Hz, 1H), 6.86 (d, J = 8.69 Hz, 1H), 3.85 (s, 3H), 3.74 (br-s, 1H), 1.96 (s, 3H); m/z (ESI); 321 [M+Na]⁺, 281 [M-OH]⁺.

Ethyl 6-bromo-2-hydroxy-2-methyl-2H-chromene-3-carboxylate (table 3, 3ab):




White solid; Mp 128-130 °C; IR: ν_{max} 3345, 3065, 2987, 1698, 1609, 1524, 1338, 1256, 1067, 941, 762 cm⁻¹; ¹H NMR (300 MHz, CDCl₃): δ 7.48 (s, 1H), 7.36-7.42 (m, 2H), 6.86 (d, J = 8.49 Hz, 1H), 4.23-4.36 (m, 2H), 3.81 (br-s, 1H), 1.95 (s, 3H), 1.37 (t, J = 7.17 Hz, 3H); ¹³C NMR (75 MHz, CDCl₃): δ 164.8, 151.5, 134.7, 132.7, 130.7, 126.7, 120.5, 118.6, 113.6, 98.0, 61.3, 27.4, 14.1; m/z (ESI); 335 [M+Na]⁺, 295 [M-OH]⁺.

Methyl 2-hydroxy-2-methyl-6-nitro-2H-chromene-3-carboxylate (table 3, 3ac):




White solid; Mp 143-145 °C; IR: ν_{max} 3386, 3068, 2984, 1698, 1615, 1507, 1338, 1267, 1053, 951, 772 cm⁻¹; ¹H NMR (300 MHz, CDCl₃+DMSO): δ 8.22 (dd, J_1 = 6.26 Hz, J_2 = 2.59 Hz, 1H), 8.19 (d, J = 2.59 Hz, 1H), 7.63 (s, 1H), 7.06 (d, J = 8.85 Hz, 1H), 3.98 (s, 3H), 3.80 (br-s, 1H), 2.02 (s, 3H); ¹³C NMR (75 MHz, CDCl₃+DMSO): δ 163.7, 157.5, 140.7, 131.2, 127.7, 126.1, 123.4, 118.2, 116.4, 98.8, 51.2, 26.8; m/z (ESI); 288 [M+Na]⁺, 248 [M-OH]⁺.

Ethyl 2-hydroxy-2-methyl-6-nitro-2H-chromene-3-carboxylate (table 3, 3ad):




White solid; Mp 132-134 °C; IR: ν_{max} 3402, 3071, 2993, 1696, 1612, 1519, 1343, 1276, 1076, 947, 774 cm⁻¹; ¹H NMR (300 MHz, CDCl₃+DMSO): δ 8.17-8.22 (m, 2H), 7.61 (m, 1H), 7.05 (d, J = 9.31 Hz, 1H), 4.29-4.38 (m, 2H), 4.02-4.11 (br-s, 1H), 2.01 (s, 3H), 1.39 (t, J = 7.39 Hz, 3H); ¹³C NMR (75 MHz, CDCl₃+DMSO): δ 162.6, 157.0, 140.2, 130.4, 127.5, 125.6, 122.9, 117.9, 115.9, 98.3, 59.6, 26.2, 13.0; m/z (ESI); 262 [M-OH]⁺.

Ethyl 6-bromo-2-hydroxy-2-isopropyl-2H-chromene-3-carboxylate (table 3, 3ae):




Semi solid; IR: ν_{max} 3068, 2967, 2934, 1702, 1626, 1471, 1361, 1284, 1136, 1052, 915, 828, 768 cm⁻¹; ¹H NMR (300 MHz, CDCl₃): δ 7.47 (s, 1H), 7.38 (dd, J_1 = 8.69 Hz, J_2 = 2.44 Hz, 1H), 7.33 (d, J = 2.44 Hz, 1H), 6.86 (d, J = 8.69 Hz, 1H), 4.50 (br-s, 1H), 4.27-4.35 (m, 2H), 2.59 (m, 1H), 1.37 (t, J = 7.17 Hz, 3H), 1.11 (d, J = 6.86 Hz, 3H), 0.90 (d, 3H); ¹³C NMR (75 MHz, CDCl₃): δ 165.8, 152.1, 134.8, 133.3, 130.8, 125.4, 120.4, 118.2, 113.2, 101.7, 61.4, 36.2, 17.4, 14.7, 14.1; m/z (ESI); 363 [M+Na]⁺, 323 [M-OH]⁺.

Tert-butyl 6-chloro-2-hydroxy-2-methyl-2H-chromene-3-carboxylate (table 3, 3af):




White solid; Mp 102-104 °C; IR: ν_{max} 3409, 3077, 2965, 2918, 1701, 1639, 1469, 1355, 1282, 1133, 1067, 915, 812, 764 cm⁻¹; ¹H NMR (300 MHz, CDCl₃): δ 7.34 (s, 1H), 7.23 (dd, J_1 = 6.10 Hz, J_2 = 2.59 Hz, 1H), 7.20 (d, J = 2.44 Hz, 1H), 6.89 (d, J = 8.54 Hz, 1H), 4.04 (br-s, 1H), 1.99 (s, 3H), 1.56 (s, 9H); ¹³C NMR (75 MHz, CDCl₃+DMSO): δ 162.7, 150.7, 130.6, 130.0, 128.6, 126.6, 124.7, 120.0, 117.1, 97.3, 80.3, 27.3, 26.5; m/z (ESI): 319 [M+Na]⁺, 279 [M-OH]⁺.

Tert-butyl 6-bromo-2-hydroxy-2-methyl-2H-chromene-3-carboxylate (table 3, 3ag):




White solid; Mp 110-112 °C; IR: ν_{max} 3412, 3061, 2974, 2927, 1700, 1632, 1480, 1367, 1293, 1148, 1071, 926, 816, 770 cm⁻¹; ¹H NMR (300 MHz, CDCl₃): δ 7.37 (dd, J_1 = 6.26 Hz, J_2 = 2.29 Hz, 1H), 7.35 (d, J = 2.29 Hz, 1H), 7.34 (s, 1H), 6.85 (d, J = 8.39 Hz, 1H), 4.01 (br-s, 1H), 1.99 (s, 3H), 1.56 (s, 9H); ¹³C NMR (75 MHz, CDCl₃+DMSO): δ 162.5, 150.9, 132.5, 130.2, 129.2, 128.3, 120.4, 117.3, 111.5, 96.9, 79.9, 27.0, 26.2; m/z (ESI): 363 [M+Na]⁺, 325 [M-OH]⁺.

Tert-butyl 2-hydroxy-2-methyl-6-nitro-2H-chromene-3-carboxylate (table 3, 3ah):




White solid; Mp 115-117 °C; IR: ν_{max} 3311, 3046, 2968, 2911, 1704, 1619, 1475, 1363, 1288, 1137, 1084, 928, 808, 766 cm⁻¹; ¹H NMR (300 MHz, CDCl₃): δ 8.17-8.21 (m, 2H), 7.46 (s, 1H), 7.04 (d, J = 8.85 Hz, 1H), 4.15 (br-s, 1H), 1.96 (s, 3H), 1.58 (s, 9H); ¹³C NMR (75 MHz, CDCl₃): δ 163.8, 157.3, 141.9, 131.2, 128.9, 127.2, 124.2, 118.7, 117.2, 99.4, 82.8, 28.1; m/z (ESI): 330 [M+Na]⁺, 290 [M-OH]⁺.

1-(6-chloro-2-hydroxy-2-methyl-2H-chromen-3-yl)ethanone (table 3, 3ai):




Yellow solid; Mp 93-95 °C; IR: ν_{max} 3337, 3051, 2996, 2924, 1656, 1622, 1560, 1477, 1376, 1273, 1209, 1076, 935, 869 cm⁻¹; ¹H NMR (300 MHz, CDCl₃): δ 7.32 (s, 1H), 7.26-7.30 (m, 1H), 7.23 (d, J = 2.44 Hz, 1H), 6.91 (d, J = 8.69 Hz, 1H), 4.58 (br-s, 1H), 2.48 (s, 3H), 1.82 (s, 3H); ¹³C NMR (75 MHz, CDCl₃): δ 198.1, 151.4, 133.9, 132.5, 128.0, 126.5, 120.0, 118.3, 98.9, 27.7, 26.6; m/z (ESI): 261 [M+Na]⁺, 221 [M-OH]⁺.

1-(6-ethoxy-2-hydroxy-2-methyl-2H-chromen-3-yl)ethanone (table 3, 3aj):




Yellow solid; Mp 143-145 °C; IR: ν_{max} 3327, 3056, 2975, 2931, 1658, 1636, 1553, 1455, 1372, 1240, 1213, 1068, 941, 763 cm⁻¹; ¹H NMR (300 MHz, CDCl₃): δ 7.34 (s, 1H), 6.76-6.96 (m, 3H), 4.18 (br-s, 1H), 4.10 (q, J = 6.79 Hz, 2H), 2.46 (s, 3H), 1.88 (s, 3H), 1.46 (t, J = 6.79 Hz, 3H); ¹³C NMR (75 MHz, CDCl₃): δ 197.8, 147.4, 142.9, 135.2, 133.1, 121.3, 120.9, 119.6, 117.4, 98.8, 65.0, 27.6, 26.6, 14.8; m/z (ESI); 271 [M+Na]⁺, 231 [M-OH]⁺.

1-(6,8-dichloro-2-hydroxy-2-methyl-2H-chromen-3-yl)ethanone (table 3, 3ak):




Yellow solid; Mp 123-125 °C; IR: ν_{max} 3324, 3068, 2983, 2932, 1667, 1637, 1558, 1456, 1381, 1259, 1215, 1065, 926, 789 cm⁻¹; ¹H NMR (300 MHz, CDCl₃): δ 7.38 (d, J = 2.09 Hz, 1H), 7.25 (s, 1H), 7.13 (s, 1H), 3.98 (br-s, 1H), 2.46 (s, 3H), 1.92 (s, 3H); ¹³C NMR (75 MHz, CDCl₃): δ 197.4, 134.6, 132.7, 132.2, 126.5, 126.3, 122.7, 120.9, 99.6, 27.7, 26.7; m/z (ESI); 295 [M+Na]⁺, 255 [M-OH]⁺.

1-(6,8-dibromo-2-hydroxy-2-methyl-2H-chromen-3-yl)ethanone (table 3, 3al):




Yellow solid; Mp 138-140 °C; IR: ν_{max} 3349, 3064, 2981, 2928, 1662, 1648, 1566, 1463, 1379, 1247, 1210, 1071, 945, 774 cm⁻¹; ¹H NMR (300 MHz, CDCl₃): δ 7.67 (d, J = 1.90 Hz, 1H), 7.31 (s, 1H), 7.23 (s, 1H), 3.86 (br-s, 1H), 2.46 (s, 3H), 1.92 (s, 3H); ¹³C NMR (75 MHz, CDCl₃): δ 197.3, 148.9, 137.7, 134.5, 132.7, 130.1, 121.4, 113.5, 111.8, 99.8, 27.8, 26.8; m/z (ESI); 383 [M+Na]⁺, 343 [M-OH]⁺.

Ethyl 2-hydroxy-2-(trifluoromethyl)-2H-chromene-3-carboxylate (table 3, 3am):



White solid; Mp 122-124 °C; IR: ν_{max} 3236, 3064, 3011, 1688, 1623, 1454, 1283, 1176, 1035, 957, 829 cm⁻¹; ¹H NMR (300 MHz, CDCl₃): δ 7.78 (s, 1H), 7.51 (s, 1H), 7.36-7.40 (m, 1H), 7.24-7.27 (m, 1H), 7.01-7.05 (m, 1H), 4.36 (q, J = 7.17 Hz, 2H), 1.40 (t, J = 7.17 Hz, 3H); ¹³C NMR (75 MHz, CDCl₃): δ 166.7, 152.5, 139.3, 133.8, 129.5, 124.5, 122.6, 120.7, 117.5, 115.9, 114.6, 62.4, 13.9; m/z (ESI); 311 [M+Na]⁺, 271 [M-OH]⁺.


Ethyl 6-bromo-2-hydroxy-2-(trifluoromethyl)-2H-chromene-3-carboxylate (table 3, 3an):



White solid; Mp 133-135 °C; IR: ν_{max} 3247, 3071, 3000, 1684, 1629, 1478, 1288, 1172, 1033, 963, 825 cm⁻¹; ¹H NMR (300 MHz, CDCl₃): δ 7.69 (s, 1H), 7.44-7.50 (m, 2H), 7.39 (d, J = 2.27 Hz, 1H), 6.94 (d, J = 9.06 Hz, 1H),


4.38 (q, $J = 6.79$ Hz, 2H), 1.40 (t, $J = 6.79$ Hz, 3H); ^{13}C NMR (75 MHz, CDCl_3): δ 166.4, 151.5, 137.8, 136.3, 131.6, 124.3, 120.5, 119.2, 117.8, 115.9, 114.7, 62.7, 13.9; m/z (ESI); 389 [M+Na] $^+$, 349 [M-OH] $^+$.

(6-bromo-2-hydroxy-2-methyl-2H-chromen-3-yl)(phenyl)methanone (table 3, 3ao):










Semi solid; IR: ν_{max} 3376, 2935, 2864, 1703, 1628, 1552, 1455, 1271, 1250, 1168, 1063, 846, 687 cm^{-1} ; ^1H NMR (300 MHz, CDCl_3): δ 7.80-7.84 (m, $J = 7.17$ Hz, 2H), 7.62-7.66 (m, 1H), 7.51 (t, $J = 7.48$ Hz, 2H), 7.42 (dd, $J_1 = 8.69$ Hz, $J_2 = 2.44$ Hz, 1H), 7.29 (d, $J_1 = 2.44$ Hz, 1H), 6.91-6.94 (m, 2H), 4.25 (br-s, 1H), 1.92 (s, 3H); ^{13}C NMR (75 MHz, CDCl_3): δ 195.2, 151.5, 136.9, 134.9, 133.9, 133.4, 133.2, 130.8, 129.8, 128.6, 120.6, 118.9, 113.8, 98.3, 27.1; m/z (ESI); 367 [M+Na] $^+$, 327 [M-OH] $^+$.


(6-bromo-2-hydroxy-2-phenyl-2H-chromen-3-yl)(phenyl)methanone (table 3, 3ap):




Semi solid; IR: ν_{max} 3413, 2924, 2854, 1701, 1633, 1565, 1475, 1289, 1246, 1173, 1067, 851, 692 cm^{-1} ; ^1H NMR (300 MHz, CDCl_3): δ 7.74-7.78 (m, 2H), 7.63-7.67 (m, 2H), 7.57-7.61 (m, 1H), 7.42-7.48 (m, 3H), 7.26-7.36 (m, 4H), 7.08 (s, 1H), 6.92 (d, $J = 8.54$ Hz, 1H), 5.04 (s, 1H); ^{13}C NMR (75 MHz, CDCl_3): δ 194.9, 150.9, 142.1, 136.1, 135.2, 133.5, 133.4, 133.0, 130.8, 129.8, 128.8, 128.6, 128.2, 125.8, 119.7, 118.8, 113.9, 99.1; m/z (ESI); 429 [M+Na] $^+$, 389 [M-OH] $^+$.











8.618
8.600
8.371
8.363
8.240
8.232
8.211
8.202
7.932
7.537
7.517
7.071
7.041

4.098
4.073
4.073
4.062
4.041
4.041
4.041



1.116
1.092
1.068







161.992
148.006
140.532
131.968
126.158
123.446
120.055
117.208
115.989



59.694







12.556





















































7.322
7.295
7.290
7.277
7.272
7.268
7.236
7.231
6.919
6.902

4.583

2.478

1.819



198.117

151.453

133.997
132.514
128.034
126.520
120.004
118.317

98.971

27.696
26.619

